Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients

British Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 67-74

  Li, Kong M ^a   Rivory, Laurent P ^b   Hoskins, Janelle ^a   Sharma, Rohini ^c   Clarke, Stephen J ^d  

^a University of Sydney   (Australia)

^b JOHNSON AND JOHNSON   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Capecitabine; Deoxyuridine; Nucleosides; Pharmacodynamic marker; Thymidine; TS inhibition

Indexed keywords

CAPECITABINE; DEOXYURIDINE; FLUOROURACIL; THYMIDINE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; GENE FREQUENCY; HAND FOOT SYNDROME; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; VARIABLE NUMBER OF TANDEM REPEAT; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DEOXYURIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; THYMIDINE;

EID: 33845425800     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02710.x     Document Type: Article

References (52)

1. Lokeich JJ, Ahlgren JD, Gullo JJ. A prespective randomized trial of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 1989; 7: 425-32.
2. Meta-Analysis. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301-8.
3. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55: 1091-7.
4. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81.
5. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-7.
6. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000; 18: 343-54.
7. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparision of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
8. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
9. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell F, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, radomised, phase III trials. Br J Cancer 2004; 90: 1190-7.
10. Rafi I, Taylor GA, Calvete JA, Boddy AV, Balmanno K, Bailey N, Lind M, Calvert AH, Webber S, Jackson RC. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clin Cancer Res 1995; 1: 1275-84.
11. Jodrell DI, Bowman A, Rye R, Byrne B, Boddy A, Rafi I, Taylor GA, Johnston A, Clendeninn NJ. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer 1999; 79: 915-20.
12. Estlin EJ, Pinkerton CR, Lewis IJ, Lashford L, McDowell H, Morland B, Kohler J, Newell DR, Boddy AV, Taylor GA, Price L, Ablett S, Hobson R, Pitsiladis M, Brampton M, Clendeninn N, Johnston A, Pearson AD. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation. Br J Cancer 2001; 84: 11-8.
13. Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003; 95: 675-82.
14. Mitchell F, Lynn S, Jackman AL. Modified high-performance liquid chromatography assay for the measurement of 2′-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs. J Chromatogr B Biomed Sci Appl 2000; 744: 351-8.
15. de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, Jackman A, Smith R, de Mulder PH, Verweij J. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002; 20: 1923-31.
16. Rees C, Beale P, Trigo JM, Mitchell F, Jackman A, Smith R, Douglass E, Judson I. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clin Cancer Res 2003; 9: 2049-55.
17. Plummer R, Rees C, Hughes A, Beale P, Highley M, Trigo J, Gokul S, Judson I, Calvert H, Jackman A, Mitchell F, Smith R, Douglass E. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clin Cancer Res 2003; 9: 1313-22.
18. Clarke SJ, Farrugia DC, Aherne GW, Pritchard DM, Benstead J, Jackman AL. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity. Clin Cancer Res 2000; 6: 285-96.
19. Horton TM, Blaney SM, Langevin A-M, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase i trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a Pediatric Oncology Group Study. Clin Cancer Res 2005; 11: 1884-9.
20. Ford HER, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL. Patterns of elevation of plasma 2′- deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 2002; 8: 103-9.
21. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51: 5579-86.
22. Yin MB, Guimaraes MA, Zhang ZG, Arredondo MA, Rustum YM. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res 1992; 52: 5900-5.
23. Jackman AL, Farrugia DC, Clarke SJ, Aherne GW, Boyle FT, Seymour L, Azab M, Kennealey G. Delayed rescue of ZD1694 toxicity in Balb/c mice with thymidine (dThd) or leucovorin (LV). Pro Am Assoc Cancer Res 1995; 36: 377.
24. McGuire JJ, Magee KL, Russell CA, Canestrare JM. Thymidylate synthase as a target for growth inhibition in metrotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines. Oncol Res 1997; 9: 139-47.
25. Smith PG, Marshman E, Newell DR, Curtin NJ. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. Br J Cancer 2000; 82: 924-30.
26. Lehman NL, Daneneberg PV. Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implication for chemotherapy. Cancer Chemother Pharmacol 2000; 45: 142-8.
27. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucl Acids Res 1987; 15: 1259-70.
28. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-7.
29. Kawakami K, Omura K, Kanehira E, Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene are associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999; 19: 3249-52.
30. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
31. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383-6.
32. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 827-30.
33. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-86.
34. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002; 17: 46-9.
35. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz H-J, Ladner RD. A novel single nucleotide polymorphism within the 5′-tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-904.
36. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-7.
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
38. National Cancer Institute Common Toxicity Criteria, v. 2.0. 1999. http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf (last accessed: 26 June 2006).
39. Li KM, Clarke SJ, Rivory LP. Quantitation of plasma thymidine by high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Anal Chim Acta 2003; 486: 51-61.
40. Li KM, Rivory LP, Clarke SJ. Rapid quantitation of plasma 2′-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B 2005; 820: 121-30.
41. Marsh S, Collie-Duguid ESR, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999; 58: 310-2.
42. Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 2000; 16: 528.
43. Mitchell F, Farrugia D, Rees C, Cunningham D, Judson I, Jackman AL. Estimation of 2′-deoxyuridine (dUrd) in human plasma by HPLC with fluorimetric detection: a pharmacodynamic marker for thymidylate synthase (TS) inhibition. Br J Cancer 1997; 75 (Suppl. 1): 25.
44. de Jonge MJA, Verweij J, van der Gaast A, Valota O, Mora O, Planting AST, Mantel MA, Bosch SVD, Lechuga MJ, Fiorentini F. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer 2002; 38: 2407-15.
45. van Laar JA, van der Wilt CL, Rustum YM, Noordhuis P, Smid K, Pinedo HM, Peters GJ. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin Cancer Res 1996; 2: 1327-33.
46. Nottebrock H, Then R. Thymidine concentration in serum and urine of different animal species and man. Biochem Pharmacol 1977; 26: 2175-9.
47. Taylor GA, Dady PJ, Harrap KR. Quantitative high-performance liquid chromatography of nucleosides and bases in human plasma. J Chromatogr 1980; 183: 421-31.
48. Holden L, Hoffbrand AV, Tattersall MH. Thymidine concentrations in human sera: variations in patients with leukaemia and megaloblastic anaemia. Eur J Cancer 1980; 16: 115-21.
49. Howell SB, Mansfield SJ, Taetle R. Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother Pharmacol 1981; 5: 221-6.
50. Dudman NPB, Deveski WB, Tattersall MHN. Radioimmunoassays of plasma thymidine, uridine, deoxyuridine and cytidine/deoxycytidine. Anal Biochem 1981; 115: 428-37.
51. Apinazzola A, Marti R, Nishino I, Andreu AL, Naini A, Tadesse S, Pela I, Zammarchi E, Donati A, Oliver A, Hirano M. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002; 277: 4128-33.
52. Zaharevitz DW, Anderson LW, Malinowski NM, Hyman R, Strong JM, Cysyk RL. Contribution of de-novo and salvage synthesis to the uracil nucleotide pool in mouse tissues and tumors in vivo. Eur J Biochem 1992; 210: 293-6.